skip to Main Content

Biogen Release a Community Update

  • 6 October 2020

This is a community update from Biogen on the efficacy of Spinraza in patients with SMA Type 2 and 3. Positive improvement were seen in both Types. For more details please see below. Biogen Community Update

Read More

MHRA approve risdiplam EAMS application

  • 17 September 2020

We currently have limited information but we wanted  to get news out to you as soon as possible. The MHRA have approved the use of risdiplam for type 1 and type 2 patients over the age of two months with no upper age limit.

Read More
Back To Top